Phospho-DNM1 (S774) Antibody

What is Dynamin-1 and why is the phosphorylation at Serine 774 significant?

Dynamin-1 (DNM1) is a ~97 kDa GTPase that catalyzes membrane fission during endocytosis. It functions by assembling into helical polymers around the necks of invaginated clathrin-coated pits, where GTP hydrolysis facilitates membrane scission. The phosphorylation at Serine 774 is particularly significant because it serves as a regulatory switch for dynamin activity.

Specifically, Ser774 phosphorylation by glycogen synthase kinase-3 beta (GSK3β) maintains dynamin-1 in an inactive state. When dephosphorylated through signaling pathways (such as EGFR downstream signaling), dynamin becomes activated and can participate in endocytic processes . This phosphorylation site is located within the proline-rich domain (PRD), affecting interactions with SH3 domain-containing binding partners critical for endocytosis .

How does the phosphorylation state of DNM1-S774 affect its cellular function?

The phosphorylation state of DNM1 at S774 directly impacts its function in several ways:

In neurons, dynamin is found constitutively phosphorylated in the cytoplasm under synaptic membranes. Upon stimulation, calcineurin dephosphorylates dynamin, allowing it to interact with the cell membrane and generate endocytic synaptic vesicles. The process terminates when Cdk5 rephosphorylates dynamin .

What is the tissue specificity of DNM1 and its phosphorylated forms?

In non-neuronal contexts, the phosphorylation/dephosphorylation cycle of DNM1 at S774 appears to be linked to the regulation of clathrin-mediated endocytosis, particularly in its early stages. This suggests that while DNM1 may be present in multiple tissues, its active regulation through S774 phosphorylation provides tissue-specific functions .

What are the optimal applications for different phospho-DNM1 (S774) antibodies?

For optimal results, select the antibody based on the planned application and target species. Western blot remains the most consistently validated application across all antibody sources, while immunohistochemistry and immunofluorescence capabilities vary by product.

How can I verify the phospho-specificity of a Phospho-DNM1 (S774) antibody?

Verification of phospho-specificity is crucial for interpreting experimental results. A multi-step approach is recommended:

• Lambda phosphatase treatment:

  • Treat one portion of your sample with lambda phosphatase (λ-PPase) before immunoblotting

  • Run both treated and untreated samples side by side

  • A true phospho-specific antibody will show dramatically reduced or eliminated signal in the phosphatase-treated lane

• Phospho-mimetic and phospho-deficient mutants:

  • Express wild-type, S774A (phospho-deficient), and S774E or S774D (phospho-mimetic) forms of DNM1

  • A phospho-specific antibody should recognize wild-type but not S774A when phosphorylation is present

  • The antibody should not recognize the S774A mutant under any condition

• Induction of phosphorylation state changes:

  • Use forskolin to stimulate phosphorylation pathways in experimental samples (as shown in R&D Systems data)

  • Use GSK3β inhibitors to reduce phosphorylation

  • Compare signal between treated and untreated samples

Evidence of phospho-specificity has been demonstrated in the literature, with Western blot of rat brain (hippocampus) tissue lysate showing specific immunolabeling of ~95 kDa dynamin phosphorylated at S774, which is eliminated by treatment with lambda phosphatase .

What experimental controls should be included when using phospho-DNM1 (S774) antibodies?

Robust experimental design requires appropriate controls:

Additionally, when working with specific cell types or tissues with lower expression, it may be helpful to enrich DNM1 using amphiphysin-II SH3 domain pulldown before detection, as demonstrated in H1299 cells where DNM1 is expressed at very low levels .

How does phosphorylation at S774 affect splice variant function in ultrafast endocytosis?

Recent research has revealed critical insights into splice variant-specific functions of dynamin-1 in ultrafast endocytosis:

The Dyn1xA splice variant is essential for ultrafast endocytosis, while Dyn1xB cannot actively participate in this process. Importantly, the phosphorylation status at S774/778 does not appear to be the determining factor in this functional difference. When researchers expressed the phospho-deficient form (S774/778A) of Dyn1xB in dynamin double knockout (DKO) neurons, it failed to rescue the ultrafast endocytosis phenotype .

This indicates that while phosphorylation at S774 is an important regulatory mechanism, the extended C-terminal domain of specific splice variants plays a critical role in determining functional specialization beyond phosphorylation status alone . This has significant implications for experimental design when studying specific endocytic pathways.

How can phospho-DNM1 (S774) antibodies help characterize the non-neuronal functions of dynamin-1?

While initially considered neuron-specific, dynamin-1 has been found to be widely expressed but maintained in an inactive state in non-neuronal cells through phosphorylation at S774 by GSK3β. Phospho-DNM1 (S774) antibodies can provide critical insights into this non-canonical role:

• Mapping activation patterns: By monitoring S774 phosphorylation states across different non-neuronal tissues and under various stimuli, researchers can identify conditions that activate dynamin-1 outside neuronal contexts.

• Pathway integration: These antibodies can help elucidate how EGFR and other growth factor signaling pathways lead to dynamin-1 activation through dephosphorylation at S774, specifically in the context of clathrin-mediated endocytosis (CME) .

• Functional competition with dynamin-2: Using phospho-specific antibodies alongside total dynamin-1 and dynamin-2 antibodies can help determine how these isoforms may compete or complement each other in non-neuronal cells. Research has shown that GSK3β inhibition accelerates CME due to increased rates of clathrin-coated pit initiation and maturation, with effects dependent on dynamin-1 but not dynamin-2 .

• Cellular localization studies: Combining immunofluorescence with phospho-DNM1 (S774) antibodies can reveal how the subcellular distribution of phosphorylated versus dephosphorylated dynamin-1 changes during different cellular processes in non-neuronal cells.

What are the technical challenges in studying phosphorylation dynamics at S774 during endocytosis?

Studying the dynamic phosphorylation/dephosphorylation of DNM1 at S774 presents several technical challenges:

• Temporal resolution limitations: Endocytosis occurs rapidly (seconds to minutes), making it difficult to capture the precise timing of phosphorylation changes using standard biochemical techniques. This challenge is particularly pronounced when studying ultrafast endocytosis, which occurs within milliseconds.

• Spatial heterogeneity: Phosphorylation events may occur locally at specific membrane domains, but tissue or cell lysate preparation dilutes this signal. Immunofluorescence with phospho-specific antibodies offers spatial information but lacks quantitative precision of biochemical methods.

• Isoform and splice variant complexity: Dynamin exists in multiple isoforms and splice variants that may be regulated differently. For example, the Dyn1xA splice variant is essential for ultrafast endocytosis, while the phosphorylation status at S774 does not affect the inability of Dyn1xB to participate in this process .

• Overlapping signals: The S774 site is in the proline-rich domain (PRD), which can be obscured by protein-protein interactions with SH3 domain-containing partners, potentially masking the epitope for antibody recognition during certain stages of endocytosis .

• Technical artifacts during sample preparation: The rapid dephosphorylation of S774 during sample handling can lead to underestimation of phosphorylation levels. Researchers should include phosphatase inhibitors during all steps of sample preparation.

Why might I observe variable results in phospho-DNM1 (S774) detection across different cell types?

Variability in phospho-DNM1 (S774) detection across cell types can stem from several factors:

• Expression level differences: While initially thought to be neuron-specific, DNM1 is expressed in non-neuronal cells but at significantly lower levels. In H1299 cells, for example, DNM1 can only be readily detected following enrichment by amphiphysin-II SH3 domain pulldown .

• Basal phosphorylation state variations: The constitutive activity of GSK3β varies across cell types, affecting the basal phosphorylation level of S774. Neurons typically show high basal phosphorylation that changes dynamically with stimulation.

• Phosphatase activity differences: Calcineurin and other phosphatases responsible for S774 dephosphorylation show variable expression and activity across cell types.

• Splice variant distribution: Different cell types express different ratios of DNM1 splice variants, which can affect epitope accessibility and function .

• Sample preparation methods: Phosphorylation status can change rapidly during sample preparation, with different cell types requiring optimized lysis conditions to preserve phosphorylation.

For optimal results across different cell types, consider enriching DNM1 before Western blot analysis when working with non-neuronal cells, and always include appropriate positive controls (such as rat brain lysate) alongside experimental samples.

How can I differentiate between phosphorylation at S774 and other phosphorylation sites on DNM1?

Dynamin-1 contains multiple phosphorylation sites, including S774 and S778, which are both important regulatory sites in the proline-rich domain. To distinguish between these sites:

• Use site-specific antibodies: Select antibodies with validated specificity for S774 phosphorylation. The antibodies described in the search results have been generated against synthetic phosphopeptides corresponding specifically to the region surrounding S774 .

• Incorporate site-specific mutants: Express S774A, S778A, and S774A/S778A (double mutant) constructs to pinpoint which phosphorylation site is being detected.

• Employ kinase inhibitors: Use specific inhibitors of GSK3β (which phosphorylates S774) versus Cdk5 (which phosphorylates S778) to modulate each site independently.

• Perform phospho-peptide mapping: Use mass spectrometry after tryptic digestion to map all phosphorylation sites and their relative abundance.

• Consider cross-reactivity testing: Test your phospho-antibody against peptides containing phosphorylated S778 or other nearby sites to rule out cross-reactivity. For example, the R&D Systems antibody (PPS004) has been shown not to cross-react with other purified substrates of Cdk5 such as Amphiphysin and Synapsin .

What are the best storage and handling practices for phospho-DNM1 (S774) antibodies?

Proper storage and handling are critical for maintaining antibody performance:

For the STJ90787 antibody, it is supplied as 1 mg/mL in PBS containing 50% Glycerol, 0.5% BSA, and 0.02% Sodium Azide . The STJA0003622 antibody is formulated as 100 µl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA, and 50% Glycerol .

Always follow the specific manufacturer's recommendations for the particular antibody you are using, as formulations may vary.

How might phospho-DNM1 (S774) antibodies contribute to understanding neurodegenerative disorders?

Dynamin-1 function and regulation are increasingly linked to neurodegenerative disorders through several mechanisms:

• Synaptic dysfunction: As a key regulator of synaptic vesicle recycling, altered DNM1 phosphorylation at S774 could contribute to synaptic transmission defects seen in early stages of neurodegenerative diseases. Phospho-DNM1 (S774) antibodies can help map these changes across different brain regions and disease stages.

• GSK3β dysregulation: GSK3β, which phosphorylates DNM1 at S774, is implicated in Alzheimer's disease pathology through tau hyperphosphorylation. Monitoring DNM1 phosphorylation could serve as a biomarker for aberrant GSK3β activity.

• Endosomal trafficking defects: Many neurodegenerative disorders feature disrupted endosomal trafficking. Since phosphorylation at S774 regulates dynamin's role in endocytosis, these antibodies could help characterize endocytic dysfunction in disease models.

• Splice variant contributions: The Dyn1xA splice variant is essential for ultrafast endocytosis , and altered splicing patterns are observed in neurological disorders. Phospho-specific antibodies used alongside splice variant analysis could reveal disease-specific dysregulation patterns.

• Therapeutic target validation: As potential therapeutics targeting dynamin or its regulatory pathways emerge, phospho-DNM1 (S774) antibodies will be critical for target engagement studies and mechanism validation.

Researchers investigating neurodegenerative diseases should consider incorporating phospho-DNM1 (S774) antibodies into their experimental workflows to monitor this specific post-translational modification as a potential biomarker or mechanistic contributor to pathology.

What role might DNM1-S774 phosphorylation play in cancer cell biology?

Emerging evidence suggests potential roles for DNM1-S774 phosphorylation in cancer biology:

• EGFR signaling modulation: Dephosphorylation at S774 occurs through EGFR downstream signaling and leads to activation of early stages of clathrin-mediated endocytosis . Given that EGFR is frequently dysregulated in cancer, altered DNM1 phosphorylation may impact receptor trafficking and signaling duration.

• Metabolic adaptation: GSK3β activity, which maintains S774 phosphorylation, is regulated by metabolic signaling including the PI3K/Akt pathway - frequently altered in cancer. Cancer cells may exploit DNM1 phosphorylation status to adapt endocytic capacity to changing metabolic demands.

• Migration and invasion: Endocytosis of integrins and other adhesion molecules is critical for cell migration. If DNM1 activation through S774 dephosphorylation contributes to this process, it could potentially influence cancer cell invasion.

• Therapeutic resistance mechanisms: Receptor recycling and degradation balance, potentially influenced by DNM1 phosphorylation state, can affect response to targeted therapies directed at receptor tyrosine kinases.

• Non-canonical functions: Beyond endocytosis, DNM1 has roles in maintaining mitochondrial morphology which could impact cancer cell metabolism and apoptotic responses.

While these connections remain to be fully explored, phospho-DNM1 (S774) antibodies provide a valuable tool for investigating these potential roles in cancer cell biology.

How can phospho-DNM1 (S774) antibodies be used in developing screens for modulators of endocytosis?

Phospho-DNM1 (S774) antibodies offer valuable tools for developing screens to identify modulators of endocytosis:

• High-content imaging screens:

  • Develop cellular assays using phospho-DNM1 (S774) immunofluorescence to quantify changes in phosphorylation status

  • Combine with markers of endocytic structures to correlate phosphorylation state with functional outcomes

  • Screen compound libraries for molecules that alter the phosphorylation/dephosphorylation balance

• ELISA-based screening platforms:

  • Develop cell-based ELISA formats using phospho-DNM1 (S774) antibodies

  • Create high-throughput formats to screen large compound libraries

  • Normalize to total DNM1 levels to identify specific modulators of phosphorylation rather than expression

• Phosphorylation pathway screens:

  • Target the GSK3β pathway (which phosphorylates S774) and phosphatases (which dephosphorylate S774)

  • Use Western blot with phospho-DNM1 (S774) antibodies to validate hits from primary screens

  • Incorporate functional endocytosis assays as secondary screens

• Splice variant-specific effects:

  • Design screens that distinguish between effects on different DNM1 splice variants

  • Include assays specific for ultrafast endocytosis, which depends on the Dyn1xA splice variant but appears independent of S774/778 phosphorylation status

• Validation in diverse cell types:

  • Validate hits across neuronal and non-neuronal cell types to identify context-specific modulators

  • Consider tissue-specific differences in DNM1 expression levels and baseline phosphorylation states